Innate Pharma (IPHA) Non Operating Income (2020 - 2022)

Innate Pharma (IPHA) reported Non Operating Income of -$557.06 for Q4 2022, up 99.98% quarter-over-quarter from -$2.3 million in Q2 2022.

Innate Pharma (IPHA) Non Operating Income (2020 - 2022) Analysis & Trends

Innate Pharma has reported Non Operating Income for 2 years, with the latest figure at -$557.06 in Q4 2022.

For the quarter ending Q4 2022, Non Operating Income changed N/A year-over-year to -$557.06; the trailing twelve-month figure through Dec 2022 stood at -$6.7 million (changed N/A YoY), and the FY2025 full-year result was $5.6 million, up 150.12% from the prior year.
Non Operating Income for Q4 2022 stood at -$557.06, up from -$2.3 million in the prior quarter.
The five-year high for Non Operating Income was -$557.06 in Q4 2022, with the low at -$2.3 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Op. Inc. (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	5.75 Mn
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	444,000.00
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	-
9	Abivax	90.15 Bn	90.15 Bn	-	9.35 Mn
10	Innate Pharma	194.19 Mn	194.19 Mn	-	-

Download Data